Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Caliper Life Sciences Forms Alliance with Horizon Discovery

Published: Thursday, April 10, 2008
Last Updated: Thursday, April 10, 2008
Bookmark and Share
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.

Caliper Life Sciences, Inc. has announced a partnership with Horizon Discovery Ltd. (Cambridge, UK) that expands Caliper Discovery Alliances and Services' (CDAS) oncology cell line and screening capabilities for testing single drugs and combination therapies.

Through this alliance, CDAS now offers genetically-defined, and isogenic human cancer cell lines that allow researchers to better identify and characterize personalized drugs targeted at a specific subset of patients.

Isogenic cell-line pairs, where one cell line contains a genetic alteration or mutation of interest and the other contains the normal gene, represent cell-based models that accurately portray specific human diseases in the context of their matched normal genetic backgrounds.

The inclusion of isogenic cell-line pairs in the discovery process enables scientists to better understand the mechanism of action of lead compounds, directly identify patient-relevant compounds from large compound libraries, re-profile existing drugs for new therapeutic indications, assess the efficacy of drug combinations, and identify potential side effects earlier in the discovery process.

"The alliance with Horizon Discovery adds significant value to existing CDAS offerings and illustrates Caliper's commitment to providing accurate in vitro and in vivo models for oncology research," said David Manyak, Executive Vice President of Drug Discovery Services, Caliper Life Sciences.

"The addition of Horizon's isogenic cell lines to our existing oncology cell proliferation panel, and the ability to correlate results from these isogenic cell lines to efficacy in specific patient populations, further solidifies Caliper's in vitro-in vivo-human (IIH) bridge. Access to these tools will enable researchers to enhance the success rate and reduce the cost of discovering targeted monotherapy or combination therapies that better treat disease with fewer adverse events," he added.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
Caliper Completes Acquisition of NovaScreen
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.
Thursday, October 06, 2005
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Zymark Supplies HTS Systems to Vertex Pharmaceuticals

Tuesday, October 15, 2002
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!